A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
A Multicenter, Open Label Phase II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AK120 in Adolescents With Moderate-to-severe AD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Guoqin Wang
- Phone Number: 86 (0760) 8987 3999
- Email: global.trials@akesobio.com
Study Locations
-
-
Guangdong
-
Dongguan, Guangdong, China
- Dongguan People's Hospital
-
Guangzhou, Guangdong, China
- The second Affiliated Hospital of Guangzhou Medical University
-
Shenzhen, Guangdong, China
- The University of Hong Kong - Shenzhen Hospital
-
-
Hunan
-
Changsha, Hunan, China
- Xiangya Hospital Central South University
-
Changsha, Hunan, China
- Hunan Pediatric Medical Union
-
-
Zhejiang
-
Ningbo, Zhejiang, China
- Ning Bo No.2 Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female subjects aged ≥12 <18 years old.
- Weight≥30kg at baseline.
- AD diagnosed at least half a year before screening.
- Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline.
Exclusion Criteria:
- Acute onset of AD in 4 weeks prior to enrollment.
- Undergone or planned surgery during the study period within the 4 weeks prior to enrollment, or unable to fully recover from surgery before enrollment.
- Previously suffered from vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC).
- Received systemic traditional Chinese medicine treatment within the 4 weeks before randomization or topical traditional Chinese medicine treatment within 1 week before randomization.
- Received treatment with other clinical study drugs within 1 month or 5 half-lives before randomization (whichever is longer).
- Have a history of allergies to any component of AK120 and/or severe allergic reactions to monoclonal antibodies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AK120 300mg every two weeks (Q2W) subcutaneous injection
Subjects with heavy weight
|
AK120 subcutaneous injection
|
|
Experimental: AK120 300mg every three weeks (Q3W) subcutaneous injection
Subjects with light weight
|
AK120 subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events(AE)
Time Frame: week -4 to week 16
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
|
week -4 to week 16
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PK evaluation: maximum plasma concentration (Cmax)
Time Frame: Baseline till last follow-up visit ( up to day 113)
|
Assessment of Cmax after AK120 administration.
|
Baseline till last follow-up visit ( up to day 113)
|
|
PK evaluation: time to maximum plasma concentration (Tmax)
Time Frame: Baseline till last follow-up visit ( up to day 113)
|
Assessment of Tmax after AK120 administration.
|
Baseline till last follow-up visit ( up to day 113)
|
|
PD evaluation: Thymus and activation regulated chemokine (TARC)/CCL17
Time Frame: Baseline till last follow-up visit ( up to day 113)
|
Percentage change in TARC/CCL17 compared to baseline.
|
Baseline till last follow-up visit ( up to day 113)
|
|
Change in Eczema Area and Severity Index (EASI) scores
Time Frame: week 0/2/4/8/12/16
|
Percentage change in EASI scores from baseline.
|
week 0/2/4/8/12/16
|
|
Change in affected Body Surface Area (BSA) scores
Time Frame: week 0/2/4/8/12/16
|
Percentage change in BSA score from baseline.
|
week 0/2/4/8/12/16
|
|
Subjects who achieved 0/1 in the Investigator's Global Assessment (IGA)
Time Frame: week 0/2/4/8/12/16
|
Percentage of subjects who achieved IGA 0/1.
|
week 0/2/4/8/12/16
|
|
Change in Children's Dermatology Life Quality Index (CDLQI) scores
Time Frame: week 0/2/4/8/12/16
|
Percentage change in CDLQI score from baseline.
|
week 0/2/4/8/12/16
|
|
Change in Patient Oriented Eczema Measure (POEM) scores
Time Frame: week 0/2/4/8/12/16
|
Percentage change in POEM score from baseline.
|
week 0/2/4/8/12/16
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AK120-208
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.